Femme et Homme
- | Pays :
- Ukraine
- Israel
- Poland
- Les 5 autres...
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this study is to assess the therapeutic potential and safety/tolerability of study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to severe allergic asthma not sufficiently controlled on current standard controller therapy. Altogether 360 patients randomized to 4 treatment groups will be included. The study compares three dose strength with placebo. Each patient receives 7 injections of study drug or undistinguishable placebo. Key outcome measures are patient reported parameters on their asthma.
Critère d'inclusion
- Moderate to Severe Allergic Asthma